MedAssets-Precyse Adds Equation

Pamplona Capital Management is building out its healthcare data services. In November 2015, the firm spent $2.7 billion to acquire publicly traded MedAssets, Inc., which served four out of every five hospitals in the United States with technology-enabled financial products and services. Once it spun off the Spend and Clinical Resource Management segment to VHA-UHC Alliance […]

CROs are back in style for M&A

Contract research organizations (CROs) are changing hands again, all over the world. Since 2010, we’ve recorded 63 transactions in total, with six announced in 2016 already. That’s a strong showing compared with five CRO deals for all of 2015, but not nearly on pace to surpass the 19 deals posted in 2014. Total combined spending, based on […]

eHealth Deals in Q1:16

Merger and acquisition activity edged up in the first quarter, up 17% to 35 transactions compared with the fourth quarter. The first quarter activity made up 27% of the 132 deals announced in the previous 12 months. Investor interest in this sector remains strong, particularly for revenue cycle management programs and data analytics technologies that […]

Arbor Pharma Targets ‘Alcohol Use Disorder’ Drug

Specialty pharma company Arbor Pharmaceuticals has acquired XenoPort, Inc. (NASDAQ: XNPT), maker of Horizant, a potential treatment for patients with “alcohol use disorder.” XenoPort develops and commercializes a portfolio of product candidates for the treatment of neurological and other disorders in the United States. The company has entered into a clinical trial agreement with the National Institute on […]

New MainStream Adds Constellation Behavioral

Constellation Behavioral Health, LLC became the fourth healthcare services company in New MainStream Capital’s portfolio on May 19. Constellation joins Anne Arundel Dermatology, MCCI Medical Group and Suncrest Home Health. Based in Mill Valley, California, Constellation offers specialized inpatient and outpatient treatment programs for addiction, mental health and co-occurring behavioral health disorders. Founder and CEO William Morrison […]

PE Firms Are Big on Dermatology

Dermatology deals are popping up like, well, you can imagine. Five acquisitions have been announced in May 2016 alone, bringing this year’s total dermatology deals to nine, and equal to the number announced in all of 2014.  Those nine deals put this year on track to surpass 2015’s total of 11 deals. Private equity firms […]

Medtronic’s Surgical Strikes

The Irish medical device maker Medtronic plc (NYSE: MDT) announced two strategic investments on May 18. The first wasn’t an acquisition, but could be a precursor to one. The company agreed to buy 15  next-generation robotic spinal systems from Israel-based Mazor Robotics Ltd. In addition, Medtronic will purchase newly issued securities representing 4% of Mazor’s outstanding shares […]

Pfizer: We’re So Over Allergan

Within hours after Pfizer (NYSE: PFE) and Allergan plc (NYSE: AGN) called off their $160 billion merger on April 26, 2016, Allergan announced a new acquisition. It’s taken a few weeks, but Pfizer is finally moving on. Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) is the target, based in Palo Alto, California. Anacor Pharmaceuticals focuses on discovering, developing and […]

Mylan Adds Topical Pharmaceuticals Business

Mylan NV (NASDAQ: MYL) still has money to spend, following its $9.9 billion deal for Swedish drug maker Meda AB in February. On Friday, May 13, RoundTable Healthcare Partners announced that its portfolio company, Renaissance Acquisition Holdings, LLC, had agreed to sell its non-sterile topical drug business to Mylan for $950 million, plus additional contingent payments […]